Latest Breaking News On - Ember trial - Page 1 : comparemela.com

Dr Vidula and Dr Lu discuses how the improved progression-free survival seen with oral selective estrogen receptor degraders (SERDs) translates to clinical practice, and the most recent NCCN guidelines.

Breast cancerFree survivalClinical practiceEstrogen receptors degradersEr her2 metastatic breast cancerProgression free survivalNccn guidelinesSerds guidelinesEmber trial